Shares of drugmaker Sanofi (SNY 2.00%) failed to keep up with the broader market in 2013, and the stock is down nearly 8% year to date. Disappointing guidance and the recent FDA rejection of multiple sclerosis treatment Lemtrada have driven shares down. However, is the market being myopic? Could Sanofi be positioned for growth, and are its shares valued attractively compared to its Big Pharma peers? Analysts Max Macaluso and David Williamson discuss this dividend stock in the following video.
This is why investors should get Sanofi on their watchlist.
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Alnylam Pharmaceuticals. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.